Cdc42-mediated inhibition of GSK-3β improves angio-architecture and lumen formation during VEGF-driven pathological angiogenesis

Microvascular Research

Volumn 81, Issue 1, 2011, Pages 34-43

  Hoang, Mien V ^a   Nagy, Janice A ^a   Senger, Donald R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Capillary morphogenesis; Cdc42; Cytoskeleton; Endothelial cells; Glycogen synthase kinase 3 (GSK 3 ); Lumens; Pathological angiogenesis; Vascular endothelial growth factor (VEGF)

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN CDC42; TDZD 8; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACTIN FILAMENT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CAPILLARY; CONTROLLED STUDY; MICROTUBULE; MICROVASCULAR ENDOTHELIAL CELL; MORPHOGENESIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD VESSELS; CDC42 GTP-BINDING PROTEIN; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MELANOMA; MICE; MICE, NUDE; MICROFILAMENTS; MICROTUBULES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; THIADIAZOLES; TRANSDUCTION, GENETIC; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650780526     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.09.001     Document Type: Article

References (54)

1. Cau J., Hall A. Cdc42 controls the polarity of the actin and microtubule cytoskeletons through two distinct signal transduction pathways. J. Cell Sci. 2005, 118:2579-2587.
2. Chae J.K., et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2573-2578.
3. Conde C., Caceres A. Microtubule assembly, organization and dynamics in axons and dendrites. Nat. Rev. Neurosci. 2009, 10:319-332.
4. Davis G.E., Camarillo C.W. An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp. Cell Res. 1996, 224:39-51.
5. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116:1175-1186.
6. Drake C.J., Fleming P.A. Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood 2000, 95:1671-1679.
7. Dugo L., et al. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit. Care Med. 2005, 33:1903-1912.
8. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 2002, 8:126-132.
9. Etienne-Manneville S. Actin and microtubules in cell motility: which one is in control?. Traffic 2004, 5:470-477.
10. Etienne-Manneville S. Cdc42-the centre of polarity. J. Cell Sci. 2004, 117:1291-1300.
11. Etienne-Manneville S., Hall A. Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity. Nature 2003, 421:753-756.
12. Forde J.E., Dale T.C. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell. Mol. Life Sci. 2007, 64:1930-1944.
13. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 2007, 74:72-84.
14. Georges P.C., et al. The yin-yang of dendrite morphology: unity of actin and microtubules. Mol. Neurobiol. 2008, 38:270-284.
15. Gundersen G.G., et al. Cortical control of microtubule stability and polarization. Curr. Opin. Cell Biol. 2004, 16:106-112.
16. Heasman S.J., Ridley A.J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 2008, 9:690-701.
17. Hoang M.V., Senger D.R. In vivo and in vitro models of mammalian angiogenesis. Methods Mol. Biol. 2005, 294:269-285.
18. Hoang M.V., et al. Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc. Natl Acad. Sci. USA 2004, 101:1874-1879.
19. Iruela-Arispe M.L., Davis G.E. Cellular and molecular mechanisms of vascular lumen formation. Dev. Cell 2009, 16:222-231.
20. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9:685-693.
21. Kim H.S., et al. Regulation of angiogenesis by glycogen synthase kinase-3beta. J. Biol. Chem. 2002, 277:41888-41896.
22. Koh W., et al. Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling. J. Cell Sci. 2008, 121:989-1001.
23. Kouklis P., et al. Cdc42 regulates the restoration of endothelial barrier function. Circ. Res. 2004, 94:159-166.
24. Le Doux J.M., et al. Complexation of retrovirus with cationic and anionic polymers increases the efficiency of gene transfer. Hum. Gene Ther. 2001, 12:1611-1621.
25. Lin R., et al. Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation. J. Biol. Chem. 1999, 274:23633-23641.
26. Liu F., et al. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB J. 2002, 16:950-962.
27. Martinez A., et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 2002, 45:1292-1299.
28. Medina M., Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Devel. 2008, 11:533-543.
29. Meijer L., et al. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 2004, 25:471-480.
30. Nagy J.A., Senger D.R. VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype. Exp. Cell Res. 2006, 312:538-548.
31. Nagy J.A., et al. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res. 1995, 55:376-385.
32. Nagy J.A., et al. Why are tumour blood vessels abnormal and why is it important to know?. Br. J. Cancer 2009, 100:865-869.
33. Nobes C.D., Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell Biol. 1999, 144:1235-1244.
34. Ozawa C.R., et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest. 2004, 113:516-527.
35. Pierce E.A., et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl Acad. Sci. USA 1995, 92:905-909.
36. Piperno G., et al. Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J. Cell Biol. 1987, 104:289-302.
37. Price L.S., et al. Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol. Biol. Cell 1998, 9:1863-1871.
38. Puls A., et al. Activation of the small GTPase Cdc42 by the inflammatory cytokines TNF(alpha) and IL-1, and by the Epstein-Barr virus transforming protein LMP1. J. Cell Sci. 1999, 112(Pt 17):2983-2992.
39. Richard L., et al. A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp. Cell Res. 1998, 240:1-6.
40. Rodriguez O.C., et al. Conserved microtubule-actin interactions in cell movement and morphogenesis. Nat. Cell Biol. 2003, 5:599-609.
41. Sanchez S., et al. The inhibition of phosphatidylinositol-3-kinase induces neurite retraction and activates GSK3. J. Neurochem. 2001, 78:468-481.
42. Schlessinger K., et al. Cdc42 and noncanonical Wnt signal transduction pathways cooperate to promote cell polarity. J. Cell Biol. 2007, 178:355-361.
43. Senger D.R., et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990, 50:1774-1778.
44. Senger D.R., et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc. Natl Acad. Sci. USA 1997, 94:13612-13617.
45. Sioussat T.M., et al. Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch. Biochem. Biophys. 1993, 301:15-20.
46. Skurk C., et al. Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ. Res. 2005, 96:308-318.
47. Tu S.S., et al. Antiapoptotic Cdc42 mutants are potent activators of cellular transformation. Biochemistry 2002, 41:12350-12358.
48. Tzima E., et al. Localized cdc42 activation, detected using a novel assay, mediates microtubule organizing center positioning in endothelial cells in response to fluid shear stress. J. Biol. Chem. 2003, 278:31020-31023.
49. Vernon R.B., Sage E.H. Between molecules and morphology. Extracellular matrix and creation of vascular form. Am. J. Pathol. 1995, 147:873-883.
50. Wedlich-Soldner R., et al. Spontaneous cell polarization through actomyosin-based delivery of the Cdc42 GTPase. Science 2003, 299:1231-1235.
51. Whelan M.C., Senger D.R. Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A. J. Biol. Chem. 2003, 278:327-334.
52. Whittle B.J., et al. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br. J. Pharmacol. 2006, 147:575-582.
53. Zeng H., et al. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. J. Exp. Med. 2006, 203:719-729.
54. Zhou F.Q., Snider W.D. Cell biology. GSK-3beta and microtubule assembly in axons. Science 2005, 308:211-214.